(1)

Regulation (EU) 2016/429 lays down disease-specific rules for the diseases listed in accordance with Article 5(1) thereof and lays down how those rules are to be applied to different categories of listed diseases. Regulation (EU) 2016/429 provides for the Member States to establish compulsory eradication programmes for the listed diseases referred to in Article 9(1), point (b), thereof, and for optional eradication programmes for listed diseases referred to in Article 9(1), point (c), thereof, and for the approval of such programmes by the Commission. That Regulation also provides for the approval or withdrawal by the Commission of the disease-free status of Member States or zones or compartments thereof with regard to certain listed diseases referred to in Article 9(1), points (b) and (c), thereof.

(2)

Commission Delegated Regulation (EU) 2020/689 (2) supplements Regulation (EU) 2016/429 and lays down the criteria for granting, maintaining, suspending and withdrawing disease-free status for Member States or zones or compartments thereof, and the requirements for the approval of compulsory or optional eradication programmes for Member States or zones or compartments thereof.

(3)

Commission Implementing Regulation (EU) 2021/620 (3) lays down implementing rules for the listed diseases referred to in Article 9(1), points (a), (b) and (c), of Regulation (EU) 2016/429 of animals, as regards the disease-free and non-vaccination status of certain Member States or zones or compartments thereof, and the approval of eradication programmes for those listed diseases. More particularly, it lists in the Annexes thereto, the Member States or zones or compartments thereof with disease-free status. The changing epidemiological situation of certain diseases makes it necessary to now amend certain Annexes to Implementing Regulation (EU) 2021/620 in order to list new disease-free Member States or zones thereof and to delete from the lists zones or compartments where disease outbreaks have been confirmed or where the conditions for maintaining the disease-free status are no longer met.

(4)

For infection with Mycobacterium tuberculosis complex (Mycobacterium bovis, M. caprae and M. tuberculosis) (MTBC), infection with Aujeszky’s disease virus (ADV), infection with bovine viral diarrhoea (BVD), infection with bluetongue virus (serotypes 1-24) (BTV), and infection with viral haemorrhagic septicaemia (VHS), several Member States have recently applied to the Commission to have disease-free status granted for part of their territory. Several Member States have also notified outbreaks of infection with rabies virus (RABV), BTV, and infection with haematopoietic necrosis (IHN) that also need to reflected in certain Annexes to Implementing Regulation (EU) 2021/620.

(5)

For infection with MTBC, Spain has submitted to the Commission information demonstrating that the conditions for recognition of disease-free status from infection with MTBC laid down in Delegated Regulation (EU) 2020/689 are fulfilled in the Autonomous Communities of the Balearic Islands, Catalonia and Murcia. Following the assessment by the Commission, those applications have been shown to comply with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for MTBC. Therefore, those zones should be listed in Part I of Annex II to Implementing Regulation (EU) 2021/620, as having disease-free status for infection with MTBC.

(6)

For infection with ADV, Italy has submitted to the Commission information demonstrating that the conditions for recognition of the disease-free status from ADV laid down in Delegated Regulation (EU) 2020/689 are fulfilled for the regions of Trento and Veneto. Following the assessment by the Commission, those applications have been shown to comply with the criteria of Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for ADV. Therefore, those zones should be listed in Part I of Annex VI to Implementing Regulation (EU) 2021/620, as having disease-free status for infection with ADV.

(7)

For infection with BVD, Germany has submitted to the Commission information demonstrating that the conditions for recognition of disease-free status from BVD laid down in Delegated Regulation (EU) 2020/689 are fulfilled for Dachau, Straubing-Bogen und Günzburg in Bavaria. Following the assessment by the Commission, those applications have been shown to comply with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for BVD. Therefore, those zones should be listed in Annex VII to Implementing Regulation (EU) 2021/620, as having disease-free status for infection with BVD.

(8)

Hungary has notified to the Commission several outbreaks of infection with RABV in Szabolcs-Szatmár-Bereg county. As the whole territory of Hungary has disease-free status from infection with RABV and is listed in Part I of Annex III to Implementing Regulation (EU) 2021/620, the disease-free status for Szabolcs-Szatmár-Bereg county should be withdrawn, and the entry for Hungary in that list should be amended accordingly.

(9)

For infection with RABV, Hungary also has submitted to the Commission an application to have an eradication programme approved for Szabolcs-Szatmár-Bereg county. Following the assessment by the Commission, that application has been shown to comply with the criteria laid down in Part II, Chapter 2, of Delegated Regulation (EU) 2020/689 for approval of eradication programmes for infection with RABV. Therefore, Szabolcs-Szatmár-Bereg county should be listed in Part II of Annex III to Implementing Regulation (EU) 2021/620, as a zone with an approved eradication programme for infection with RABV.

(10)

Portugal has notified to the Commission outbreaks of infection with BTV serotype 4 in Aveiro, Bragança, Coimbra, Guarda and Viseu districts, affecting also the surrounding districts. As those districts have disease-free status and are listed in Part I of Annex VIII to Implementing Regulation (EU) 2021/620, their disease-free status for infection with BTV should be withdrawn, and the entry for Portugal in that list should be amended accordingly.

(11)

Spain has notified to the Commission outbreaks of infection with BTV serotype 4 in the Toledo province in the Autonomous Community of Castilla-La Mancha, and in the Salamanca province in the Autonomous Community of Castilla y Leon affecting also areas in the Avila and Zamora province. As those areas have disease-free status and are listed in Part I of Annex VIII to Implementing Regulation (EU) 2021/620, their disease-free status for infection with BTV should be withdrawn, and the entry for Spain in that list should be amended accordingly.

(12)

As regards infection with BTV, Spain has also submitted to the Commission information demonstrating that the conditions for recognition of disease-free status from BTV are fulfilled for certain regions of the Autonomous Communities of Aragón and of Navarra and in certain regions in the Basque Autonomous Community. Following the assessment by the Commission, that application has been shown to comply with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for BTV. As infection with BTV has been successfully eradicated from those Autonomous Communities, the whole territory of those Autonomous Communities, should, therefore, be listed in Part I of Annex VIII to Implementing Regulation (EU) 2021/620, as having disease-free status for infection with BTV.

(13)

As regards infection with BTV, Germany has submitted to the Commission information demonstrating that the conditions for recognition of disease-free status from BTV are fulfilled for Bundesland Saarland and for certain parts of Bundesland Rhineland-Palatinate. Following the assessment by the Commission, that application has been shown to comply with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for BTV. Therefore, that zone should be listed in Part I of Annex VIII to Implementing Regulation (EU) 2021/620, as having disease-free status for infection with BTV.

(14)

As regards VHS, Finland has provided information which demonstrates that the conditions for the recognition of disease-free status from VHS are fulfilled for the province of Åland. That information complies with the criteria laid down in Part II, Chapter 4, of Delegated Regulation (EU) 2020/689 for the granting of disease-free status for VHS. As VHS has been successfully eradicated from the province of Åland, the whole territory of Finland should, therefore, be listed in Part I of Annex XII to Implementing Regulation (EU) 2021/620, as having disease-free status for VHS.

(15)

In addition, Finland has notified to the Commission an outbreak of IHN in the province of Åland, in an area which is listed as having disease-free status in Annex XIII to Implementing Regulation (EU) 2021/620. The disease-free status of the infected area should therefore be withdrawn and that compartment should be deleted from Part I of that Annex, and the entry for that Member State in that list should be amended accordingly.

(16)

Annexes II, III, VI, VII, VIII, XII and XIII to Implementing Regulation (EU) 2021/620 should therefore be amended accordingly.

(17)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,